Keyword: Acadia Pharmaceuticals
Acadia was stung hard after its schizophrenia hopes for Nuplazid fell flat back in late July. Fortunately, dementia-related psychosis shows promise.
With psychosis med Nuplazid facing a DOJ probe and schizophrenia flop, Acadia hopes a new round of TV ads will help court more patients.
Acadia’s Nuplazid is under the gun after prosecutors launched a marketing probe in March. Now the drug has to cope with a trial flop in schizophrenia.